Clinical Guideline (CANMAT 2016) Discordance of Medications for Patients with Major Depressive Disorder in China.

Yuncheng ZhuZhiguo WuDongmei ZhaoXiaohui WuRuoqiao HeZuowei Wang Dai-Hui Peng Yi-Ru Fang

Published in: Neuropsychiatric disease and treatment (2023)

SSRIs were the first choice in the first therapy, while the proportion of those drugs decreased during the follow-up therapy and were replaced by SNRIs. Plenty of combined pharmacotherapies were directly selected as the first trial of patients, which was inconsistent with guideline recommendations.

Keyphrases

major depressive disorder
end stage renal disease
bipolar disorder
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
study protocol
prognostic factors
randomized controlled trial
stem cells
bone marrow
phase ii
drug induced
open label